API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/minerva-again-tangled-web-rejection-after-fda-nixes-schizophrenia-drug-2nd-time
https://www.globenewswire.com/news-release/2023/05/10/2665474/32445/en/Minerva-Neurosciences-Announces-Update-on-its-New-Drug-Application-NDA-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html
https://www.globenewswire.com/news-release/2023/05/01/2658173/32445/en/Minerva-Neurosciences-Announces-the-NDA-Filing-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html
https://www.globenewswire.com/news-release/2022/10/17/2535492/32445/en/Minerva-Neurosciences-Receives-Refusal-to-File-Letter-from-FDA-for-its-New-Drug-Application-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html
https://www.globenewswire.com/news-release/2022/08/22/2502130/32445/en/Minerva-Neurosciences-Submits-New-Drug-Application-to-FDA-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Patients-with-Schizophrenia.html
https://www.globenewswire.com/news-release/2021/11/03/2326391/32445/en/Minerva-Neurosciences-Announces-FDA-Recommendation-for-Type-C-Meeting-to-Discuss-Evidence-for-Use-of-Roluperidone-as-Monotherapy-for-the-Treatment-of-Negative-Symptoms-in-Patients-.html
https://www.globenewswire.com/news-release/2021/03/08/2188587/0/en/Minerva-Neurosciences-Reports-Fiscal-2020-Fourth-Quarter-and-Year-End-Financial-Results-and-Business-Updates.html
https://endpts.com/the-fda-spells-out-4-reasons-why-it-hates-minervas-nda-ideas-but-the-biotech-is-going-for-it-anyway/
https://www.clinicaltrialsarena.com/news/roluperidone-schizophrenia-data/
https://endpts.com/minerva-suffers-another-cns-defeat-eli-lilly-wins-ok-for-tau-based-alzheimers-diagnostic/
https://www.einpresswire.com/article/508958665/minerva-neurosciences-announces-completion-of-patient-enrollment-in-phase-3-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-in